A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor recep...
A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer
About this item
Full title
Author / Creator
Publisher
China: Chinese Anti-Cancer Association (CACA), Cancer Biology & Medicine
Journal title
Language
English
Formats
Publication information
Publisher
China: Chinese Anti-Cancer Association (CACA), Cancer Biology & Medicine
Subjects
More information
Scope and Contents
Contents
According to the latest GLOBOCAN 2020 statistics on cancer incidence and mortality from the International Agency for Research on Cancer, 45.3% of new liver cancer cases and 47.1% of liver cancer deaths are estimated to occur in China. In the REFLECT trial, lenvatinib has been shown to be similar to sorafenib for overall survival (OS). Because soraf...
Alternative Titles
Full title
A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2627994700
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2627994700
Other Identifiers
ISSN
2095-3941
DOI
10.20892/j.issn.2095-3941.2021.0520
